Tang, Joseph D.
Mills, Matthew N.
Nakashima, Justyn
Dohm, Ammoren E.
Khushalani, Nikhil I.
Forsyth, Peter A.
Vogelbaum, Michael A.
Wuthrick, Evan J.
Yu, Hsiang-Hsuan M.
Oliver, Daniel E.
Liu, James K. C.
Ahmed, Kamran A.
Article History
Received: 26 November 2023
Accepted: 13 December 2023
First Online: 3 February 2024
Declarations
:
: Joseph D. Tang: no disclosures. Matthew N. Mills: no disclosures.Justyn Nakashima: no disclosures.Ammoren E. Dohm: no disclosures.Nikhil I. Khushalani: personal consulting fees from Astra-Zeneca, Bristol Myers Squibb, Incyte, Iovance, Merck, Novartis, Nektar, Replimune, Regeneron, Jounce, Castle Biosciences, and Instill Bio; receives research funding from Bristol Myers Squibb, Merck, Novartis, Replimune, Celgene, Regeneron, HUYA Biopharmaceuticals, and GlaxoSmithKline; and has common stock holdings in Bellicum Pharmaceuticals, Amarin Corp, and Asensus Surgical. Peter A. Forsyth: has funding from Pfizer and Celgene and is on the advisory boards of Novocure, BTG, Inovio, AbbVie, Ziopharm, Tocagen, and Pfizer. Michael A. Vogelbaum: has indirect equity and royalty interests in Infuseon Therapeutics, Inc. and has received honoraria from Tocagen, Inc. and Celgene. Evan J. Wuthrick: has served on the advisory board and has received honoraria from Bayer, has received research funding from Bristol-Myers Squibb, and has intellectual property: cGMP as protector for chemotherapy and radiation. Hsiang-Hsuan Michael Yu: has received speaker’s honoraria from BrainLab and is on the advisory boards of Novocure and AbbVie. Daniel E. Oliver: no disclosures. James K.C. Liu: no disclosures. Kamran A. Ahmed: has received research funding from Bristol-Myers Squibb, Eli Lilly, and Genentech.